Albumin Excipient Global Market Report 2025

Albumin excipient refers to a protein derived from blood, serving as an inactive ingredient in pharmaceutical formulations. As an excipient, it functions as a carrier or stabilizer for the active pharmaceutical ingredient.

The primary product types of albumin excipients include human serum albumin and recombinant albumin. Human serum albumin, the principal protein synthesized by the liver and found in human plasma, is a key component. These albumin excipients find applications across various end-users, including the pharmaceutical and biotechnology industry, research institutes, and other related fields.

The albumin excipient market research report is one of a series of new reports from The Business Research Company that provides albumin excipient market statistics, including albumin excipient industry global market size, regional shares, competitors with an albumin excipient market share, detailed albumin excipient market segments, market trends and opportunities, and any further data you may need to thrive in the albumin excipient industry. This albumin excipient market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The albumin excipient market size has grown strongly in recent years. It will grow from$4.85 billion in 2024 to $5.2 billion in 2025 at a compound annual growth rate (CAGR) of 7.1%. The growth in the historic period can be attributed to biopharmaceutical industry growth, increased adoption of biologics, risen prevalence of chronic diseases, clinical advancements and drug innovation, increased focus on drug delivery

The albumin excipient market size is expected to see strong growth in the next few years. It will grow to $6.77 billion in 2029 at a compound annual growth rate (CAGR) of 6.8%. The growth in the forecast period can be attributed to continued biopharmaceutical expansion, growing biologics pipeline, rising geriatric population, global vaccination initiatives, increasing drug development investments. Major trends in the forecast period include biodegradable and biocompatible properties, collaborations and partnerships in research, regulatory compliance and quality standards, application in cell therapy, customization and tailored solutions.

The increasing prevalence of chronic diseases is expected to drive the growth of the albumin excipient market in the future. Chronic diseases are illnesses that persist for three months or longer and can worsen over time. Albumin, the most abundant circulating protein in plasma, serves as a blood volumizer and a versatile protein carrier, aiding in drug targeting and enhancing the pharmacokinetic profile of peptide or protein-based medications used to treat various conditions, including cancer and diabetes. For instance, in February 2024, the World Health Organization, a United Nations agency based in Switzerland, projected that more than 35 million new cancer cases will occur by 2050, representing a 77% increase from an estimated 20 million cases in 2022. Thus, the rising prevalence of chronic diseases is a significant factor propelling the growth of the albumin excipient market.

The increase in healthcare expenditures is expected to drive the growth of the albumin excipient market in the future. Health expenditures encompass all costs related to delivering health services, family planning initiatives, nutrition programs, and emergency health assistance. Rising healthcare spending positively impacts the albumin excipient market by providing increased financial support for the development and use of advanced albumin-based formulations in pharmaceuticals and biopharmaceuticals. For example, the Canadian Institute for Health Information, a non-profit organization based in Canada, reported in November 2023 that total health expenditure is projected to reach $344 billion in 2023, indicating a modest growth of 2.8% compared to the previous year. Therefore, the rise in healthcare expenditures is a significant factor driving the growth of the albumin excipient market.

Leading companies in the albumin excipient market are increasingly adopting a strategic partnership approach to support the biotechnology and pharmaceutical sectors. Strategic partnerships involve companies leveraging each other's strengths and resources to achieve mutual benefits and success. For example, in October 2023, ARTES Biotechnology GmbH, a Germany-based biotechnology firm, partnered with Basic Pharma, a pharmaceutical company based in the Netherlands, to enhance recombinant protein production. Through this collaboration, they aim to optimize the supply chain and reduce the time-to-market for new products in the pharmaceutical sector.

Major companies in the albumin excipient market are also engaging in collaborations to foster new relationships and jointly develop innovative medicines. In June 2023, Albumedix Ltd., a UK-based pharmaceutical company, expanded its collaboration with Valneva SE to include Valneva's newly approved inactivated COVID-19 vaccine, VLA2001. This collaboration aims to address significant unmet medical needs, with Albumedix's rHA making a substantial contribution to the vaccine's manufacturing process. Valneva SE, a France-based biotech company, specializes in the development, manufacturing, and commercialization of prophylactic vaccines for infectious diseases, including VLA2001, the only whole virus, inactivated, adjuvanted vaccine candidate in clinical trials against COVID-19 in Europe.

In September 2022, Sartorius AG, a Germany-based pharmaceutical and laboratory equipment manufacturer, made a strategic acquisition by purchasing Albumedix for $503 million. This acquisition strengthens Sartorius Inc.'s cell culture media business by expanding its portfolio of bioprocess solutions. This strategic move enhances Sartorius Inc.'s capabilities and market presence in the rapidly evolving field of bioprocessing. Albumedix, a UK-based company, focuses on the development and manufacturing of recombinant human albumin products, contributing to the advancement of biopharmaceuticals.

Major companies operating in the albumin excipient market include Albumin Therapeutics LLC, Biotest AG, CSL Behring,Grifols S.A., HiMedia Laboratories LLC, InVitria Inc., Medxbio Pte Ltd., Octapharma AG, RayBiotech Inc., SeraCare Life Sciences Inc., Sigma-Aldrich Pty. Ltd., Hualan Biological Engineering Inc., Kedrion Biopharma, LFB USA Inc., Shanghai RAAS Blood Products Co. Ltd., Baxter International Inc., Merck KGaA, Thermo Fisher Scientific Inc., Albumedix A/S, Bio Products Laboratory Ltd., Shire Plc., Ventria Bioscience Inc., Novartis AG, China Biologic Products Holdings Inc., ProMetic Life Sciences Inc., Sanquin, Biopharma, Takeda Pharmaceutical Company Limited, FUJIFILM Irvine Scientific Inc.

North America was the largest region in the Albumin Excipient market in 2024. Asia-Pacific is expected to be the fastest-growing region in the global albumin excipient market report during the forecast period. The regions covered in the albumin excipient market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the albumin excipient market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain

The albumin excipient market consists of sales of ovalbumin, and bovine serum albumin. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Albumin Excipient Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on albumin excipient market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for albumin excipient ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The albumin excipient market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Product: Human Serum Albumin; Recombinant Albumin
• 2) By End-Users: Pharmaceutical And Biotechnology Industry; Research Institutes; Other End Users
• Subsegments:
• 1) By Human Serum Albumin: 5% Human Serum Albumin; 20% Human Serum Albumin
• 2) By Recombinant Albumin: Recombinant Human Serum Albumin; Recombinant Bovine Serum Albumin
• Companies Mentioned: Albumin Therapeutics LLC; Biotest AG; CSL Behring;Grifols S.A.; HiMedia Laboratories LLC
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.